← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 31, 2002Last known activity
Feb 1, 2026
Timeline
No events for the selected filters.
Drugs by trial phase (49 distinct, 43 trials)
Phase 4 (13 own, 0 via acquisition)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Blood Coagulation Disorders
- Cardiovascular Diseases
- Coronavirus Infections
- Diabetes Mellitus, Type 2
- Epistaxis
- Hemorrhage
- Hemostatic Disorders
- Severe Acute Respiratory Syndrome
- Subarachnoid Hemorrhage
- Telangiectasia, Hereditary Hemorrhagic
- Telangiectasis
- Thromboembolism
- Venous Thromboembolism
- Wounds and Injuries
Recent trials (50)
- NCT07262008CollaboratorPhase 3Feb 1, 2026
- NCT07301632OfficialPhase 2Dec 17, 2025
- NCT07301632Lead sponsorPhase 2Dec 17, 2025
- NCT07017270Lead sponsorPhase 4Jul 31, 2025
- NCT06818721Lead sponsorPhase 2Mar 31, 2025
- NCT06843187Lead sponsorPhase 2Feb 28, 2025
- NCT06843187OfficialPhase 2Feb 28, 2025
- NCT06843174Lead sponsorPhase 4Feb 19, 2025
- NCT06809998OfficialPhase 1/Phase 2Jan 24, 2025
- NCT06809998Lead sponsorPhase 1/Phase 2Jan 24, 2025
- NCT06823596CollaboratorN/AJan 14, 2025
- NCT06792214CollaboratorPhase 4Jan 3, 2025
- NCT06731335Lead sponsorPhase 2Dec 31, 2024
- NCT06386003Lead sponsorPhase 2Aug 31, 2024
- NCT06495294OfficialN/AAug 31, 2024
Details
- Last known activity
- Feb 1, 2026